Terry J. Rosen - Mar 7, 2022 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role: Chief Executive Officer, Director
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Stock symbol: RCUS
Transactions as of: Mar 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/10/2022, 04:04 PM
Previous filing: Dec 20, 2021
Next filing: Jun 10, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCUS	Common Stock	Gift	$0	-321K	-100%	$0.00^*	0	Mar 7, 2022	Rosen GRAT No. 2	F1
transaction	RCUS	Common Stock	Award	$0	+65K	+30.72%	$0.00	277K	Mar 8, 2022	Direct	F2
holding	RCUS	Common Stock						3.43M	Mar 7, 2022	By The Rosen Family Trust	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCUS	Stock Option (right to buy)	Award	$0	+275K		$0.00	275K	Mar 8, 2022	Common Stock	275K	$33.03	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	321,074 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust. The remaining 62,930 shares were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13.
F2	Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company.
F3	62,930 shares previously held by the reporting person in Rosen GRAT No. 2 were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13.
F4	The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company.